ASSOCIATION BETWEEN H. PYLORI ANTIBODY AND NON-ALCOHOLIC STEATOHEPATITIS

Mazin Shaker Jaber; Ahmed Razzaq Wajid; Sahib Shiblawi Sumiea

doi:10.61796/jhsm.v1i3.23

Authors

Mazin Shaker Jaber Specialized Biology, Diwaniyah Health Department, Al-Hayat Psychiatric Hospital, Iraq
Ahmed Razzaq Wajid General Directorate of Education of Al-Qadisiyah, Iraq
Sahib Shiblawi Sumiea Specialized Molecular Biology, Diwaniyah Health Department, Main Blood Transfusion Center, Iraq

DOI:

https://doi.org/10.61796/jhsm.v1i3.23

Keywords:

Iraq, Non-alcoholic steatohepatitis, H. pylori antibody

Abstract

Objective: The disorder known as nonalcoholic fatty liver disease affects the liver as a result of normal fat accumulation. Another type of fatty liver is associated with alcohol consumption: nonalcoholic steatohepatitis (NASH), which is more severe than NAFLD. Research suggests that Helicobacter pylori infection and NAFLD may be related. Objective: The purpose of this research is to examine the connection between infection with Helicobacter pylori and NASH through specific tests to assess liver function, metabolic measurements, and the severity of infection progression. Method: At Al-Diwaniyah Gastroenterol Hospital in Al-Diwaniyah, 70 patients with nonalcoholic fatty liver diseases (NAFLD) as 60 healthy volunteers participated in this comparative study. A venous blood sample was taken in order to identify Helicobacter pylori infection. Serum immunoglobulin G (IgG) as fecal H. pylori antigen were measured using an enzyme-linked immunosorbent test (ELISA). Other laboratory parameters were examined, including liver enzymes (aspartate aminotransferase (AST) and alanine aminotransferase (ALT)). NAFLD was diagnosed & its severity assessed using ultrasound. Results: The NAFLD patient group consisted of 40 females, whereas 28 females made up the control group, 35 participants in the non-alcoholic fatty liver disease NAFLD group had a grade 1 infection, 32 had grade 2, and 3 had grade 3. Serum IgG antibody levels for Helicobacter pylori were positive in 36 patients in the NAFLD group and in 35 patients in the control group. The mean (± standard deviation) level of H. pylori IgG antibody was higher in the NAFLD group than in the control group. Additionally, the NAFLD group had a higher frequency of fecal pylori antigen than the controls group (25 vs. 17 individuals). The frequency of H. When using serum IgG antibody results rather than stool H. pylori Ag data, pylori infection was higher in both the NAFLD and control groups. Novelty: This study introduces a novel comparative evaluation by simultaneously analyzing both serum IgG antibodies and fecal antigens alongside ultrasound-graded NAFLD severities to highlight the distinct diagnostic discrepancies between systemic and active localized H. pylori infections in metabolic liver disorders. By uncovering a higher positional frequency of fecal antigens specifically within the NAFLD cohort, this research offers new clinical insights into how gastrointestinal pathogen loads might correlate directly with the progressive staging of nonalcoholic fatty liver accumulation.

References

[1] E. C. Valadares, M. A. Gestic, M. P. Utrini, and others, “Is {Helicobacter pylori} Infection Associated with Nonalcoholic Fatty Liver Disease in Individuals Undergoing Bariatric Surgery? Cross-Sectional Study,” Sao Paulo Med. J., vol. 141, p. e2022517, 2023.

[2] K. Tokushige, K. Ikejima, M. Ono, and others, “Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis 2020,” Hepatol. Res., vol. 51, pp. 1013–1025, 2021.

[3] E. Buzzetti, M. Pinzani, and E. A. Tsochatzis, “The Multiple-Hit Pathogenesis of Non-Alcoholic Fatty Liver Disease ({NAFLD}),” Metabolism, vol. 65, pp. 1038–1048, 2016.

[4] M. G. Mavilia-Scranton, G. Y. Wu, and M. Dharan, “Impact of {Helicobacter pylori} Infection on the Pathogenesis and Management of Nonalcoholic Fatty Liver Disease,” J. Clin. Transl. Hepatol., vol. 11, p. 670, 2023.

[5] P. Yan, B. Yu, M. Li, and others, “Association between Nonalcoholic Fatty Liver Disease and Infection in Dali City, China,” Saudi Med. J., vol. 42, p. 735, 2021.

[6] K. Ito, Y. Yamaoka, H. Ota, and others, “Adherence, Internalization, and Persistence of {Helicobacter pylori} in Hepatocytes,” Dig. Dis. Sci., vol. 53, pp. 2541–2549, 2008.

[7] A. E. Khalil, H. E. Lashin, M. M. Metwally, and others, “A Study of {Helicobacter pylori} Infection in Patients with Non-Alcoholic Fatty Liver Disease,” Egypt. J. Hosp. Med., vol. 77, pp. 4855–4860, 2019.

[8] X. Chen, R. Peng, D. Peng, and others, “An Update: Is There a Relationship between {H. pylori} Infection and Nonalcoholic Fatty Liver Disease? Why Is This Subject of Interest?,” Front. Cell. Infect. Microbiol., vol. 13, p. 1282956, 2023.

[9] K. Wijarnpreecha, C. Thongprayoon, P. Panjawatanan, W. Manatsathit, V. Jaruvongvanich, and P. Ungprasert, “{Helicobacter pylori} and Risk of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis,” J. Clin. Gastroenterol., vol. 52, pp. 386–391, 2018.

[10] B. G. Zhou, H. J. Yang, W. Xu, K. Wang, P. Guo, and Y. W. Ai, “Association between {Helicobacter pylori} Infection and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Observational Studies,” Helicobacter, vol. 24, p. e12576, 2019, doi: 10.1111/hel.12576.

[11] E. C. Valadares, M. A. Gestic, M. P. Utrini, and others, “Pre-Operative Screening of {Helicobacter pylori} in Bariatric Patients: Is Histopathological Analysis Necessary?,” Arq. Gastroenterol., vol. 59, no. 2, pp. 275–280, 2022.

[12] D. M. Tang and S. Kumar, “The Association between {Helicobacter pylori} Infection and Nonalcoholic Fatty Liver Disease,” Curr. Gastroenterol. Rep., vol. 19, no. 2, p. 5, 2017, doi: 10.1007/s11894-017-0545-1.

[13] A. Mantovani, T. Turino, A. Altomari, and others, “Association between {Helicobacter pylori} Infection and Risk of Nonalcoholic Fatty Liver Disease: An Updated Meta-Analysis,” Metabolism, vol. 96, pp. 56–65, 2019, doi: 10.1016/j.metabol.2019.04.012.

[14] F. Bessone, M. Dirchwolf, M. A. Rodil, M. V Razori, and M. G. Roma, “Drug-Induced Liver Injury in the Context of Nonalcoholic Fatty Liver Disease: A Physiopathological and Clinical Integrated View,” Aliment. Pharmacol. & Ther., vol. 48, no. 9, pp. 892–913, 2018.

[15] A. Adenote, I. Dumic, C. Madrid, and others, “{NAFLD} and Infection: A Nuanced Relationship,” Can. J. Gastroenterol. Hepatol., vol. 2021, p. 5556354, 2021.

[16] M. Banic, F. Franceschi, Z. Babic, and A. Gasbarrini, “Extragastric Manifestations of {Helicobacter pylori} Infection,” Helicobacter, vol. 17, no. Suppl. 1, pp. 49–55, 2012.

[17] E. M. Rabelo-Goncalves, B. M. Roesler, and J. M. Zeitune, “Extragastric Manifestations of {Helicobacter pylori} Infection: Possible Role of the Bacterium in Liver and Pancreas Diseases,” World J. Hepatol., vol. 7, no. 30, pp. 2968–2979, 2015.

[18] S. A. Polyzos, J. Kountouras, C. Zavos, and G. Deretzi, “The Association between {Helicobacter pylori} Infection and Insulin Resistance: A Systematic Review,” Helicobacter, vol. 16, no. 2, pp. 79–88, 2011.

[19] M. Li, Z. Shen, and Y. M. Li, “Potential Role of {Helicobacter pylori} Infection in Nonalcoholic Fatty Liver Disease,” World J. Gastroenterol., vol. 19, no. 41, pp. 7024–7031, 2013.

[20] P. Avenaud et al., “Detection of {Helicobacter} Species in the Liver of Patients with and without Primary Liver Carcinoma,” Cancer, vol. 89, no. 7, pp. 1431–1439, 2016.

[21] S. A. Polyzos et al., “{Helicobacter pylori} Infection in Patients with Nonalcoholic Fatty Liver Disease,” Metabolism, vol. 62, no. 1, pp. 121–126, 2013.

[22] B. Pourakbari et al., “Diagnosis of {Helicobacter pylori} Infection by Invasive and Noninvasive Tests,” Brazilian J. Microbiol., vol. 44, no. 3, pp. 795–798, 2013.

[23] K. Okushin et al., “{Helicobacter pylori} Infection Is Not Associated with Fatty Liver Disease Including Non-Alcoholic Fatty Liver Disease: A Large-Scale Cross-Sectional Study in Japan,” BMC Gastroenterol., vol. 15, p. 25, 2015.

[24] M. K. Baeg, S. K. Yoon, S. H. Ko, Y. S. Noh, I. S. Lee, and M. G. Choi, “{Helicobacter pylori} Infection Is Not Associated with Nonalcoholic Fatty Liver Disease,” World J. Gastroenterol., vol. 22, no. 8, pp. 2592–2600, 2016.

[25] R. Jamali, A. Mofid, H. Vahedi, R. Farzaneh, and S. Dowlatshahi, “The Effect of {Helicobacter pylori} Eradication on Liver Fat Content in Subjects with Non-Alcoholic Fatty Liver Disease: A Randomized Open-Label Clinical Trial,” Hepat. Mon., vol. 13, no. 12, p. e14679, 2013.

[26] J. Baj, A. Forma, M. Sitarz, and others, “{Helicobacter pylori} Virulence Factors: Mechanisms of Bacterial Pathogenicity in the Gastric Microenvironment,” Cells, vol. 10, p. 27, 2021.

[27] T. A. Jones, D. Z. Hernandez, Z. C. Wong, and others, “The Bacterial Virulence Factor {CagA} Induces Microbial Dysbiosis That Contributes to Excessive Epithelial Cell Proliferation in the {Drosophila} Gut,” PLOS Pathog., vol. 13, p. e1006631, 2019.